This clinical trial is focused on studying the effects of a new treatment for acute ischemic stroke, a condition where blood flow to a part of the brain is blocked, leading to potential brain damage. The treatment being tested is called redasemtide (also known by its code name S-005151), which is administered as a lyophilized powder through an intravenous infusion. The study will compare the effects of redasemtide with a placebo in adult participants who have experienced an acute ischemic stroke and are not eligible for certain standard treatments like tissue plasminogen activator or thrombectomy.

The purpose of the study is to evaluate how effective and safe redasemtide is compared to a placebo. Participants in the study will receive either the redasemtide treatment or a placebo, and their progress will be monitored over a period of time. The study will involve regular check-ups and assessments to track the participants’ recovery and any changes in their condition. The main goal is to see if redasemtide can improve outcomes for people who have had an acute ischemic stroke.

Throughout the study, participants will be evaluated using various measures, including the mRS score, which assesses the degree of disability or dependence in daily activities, and the NIHSS score, which measures the severity of stroke symptoms. These assessments will help determine the effectiveness of the treatment. The study aims to provide valuable information on whether redasemtide can be a beneficial treatment option for those affected by acute ischemic stroke.